PP45 Budget Impact Analysis Of Including Bictegravir/Emtricitabine/Tenofovir Alafenamide In First-Line Antiretroviral Therapy For HIV/AIDS In Chile’s Explicit Health Guarantees
Daniela Sugg, Maximiliano Alarcón, Dino Sepúlveda, Moisés Russo · 2025
Read PP45 Budget Impact Analysis Of Including Bictegravir/Emtricitabine/Tenofovir Alafenamide In First-Line Antiretroviral Therapy For HIV/AIDS In Chile’s Explicit Health Guarantees by Daniela Sugg, Maximiliano Alarcón, Dino Sepúlveda, Moisés Russo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768828.txt.
Description
Daniela Sugg and co-authors price a policy question for Chile: what happens to the health budget if a newer HIV pill joins the guaranteed first-line list, in a 2025 abstract. The single-pill regimen combines three drugs and would stand in for an older trio. The team modeled the state system's costs from 2025 to 2027 under current prices, changed usage, and the new option's entry.
The answer was calm: no meaningful budget impact. Central buying by the national supply center squeezed prices enough to absorb the switch, with a large price drop in recent data doing much of the work. The analysis gives the ministry a money map beside the medical case.
Catalog record
| CREATOR | Daniela Sugg, Maximiliano Alarcón, Dino Sepúlveda, Moisés Russo |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |